Plant Name: Albizia amara
Taxonomic Information:
Plant ID: NPO19601
Plant Latin Name: Albizia amara
Taxonomy Genus: Albizia
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
1179215
Plant-of-the-World-Online:
473171-1
Used in Medicines:
Country/Region:
Kenya; Tanzania; Rwanda; IndiaTraditional Medicine System:
Geographical Distribution:
Tanzania; India; Rwanda; Mozambique; Somalia; Sri Lanka; Kenya
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| PIM1; AURKB; AURKA; KDR; | |
| GFER; | |
| RAB9A; NPC1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.245E-06 | 2.099E-02 | AURKA, AURKB, KDR, PIM1 |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 1.928E-06 | 2.099E-02 | AURKA, AURKB |
| MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 2.892E-06 | 2.099E-02 | AURKA, AURKB |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.667E-06 | 3.909E-02 | CYP1A1, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0035404; histone-serine phosphorylation | 1.271E-05 | 3.909E-02 | AURKA, AURKB |
| CC | GO:0043226; organelle | GO:0000780; condensed nuclear chromosome, centromeric region | 1.271E-05 | 3.909E-02 | AURKA, AURKB |
| CC | GO:0043226; organelle | GO:0031616; spindle pole centrosome | 1.271E-05 | 3.909E-02 | AURKA, AURKB |
| BP | GO:0009987; cellular process | GO:0060548; negative regulation of cell death | 3.102E-05 | 5.254E-02 | AURKA, AURKB, KDR, NPC1, PIM1 |
| MF | GO:0005488; binding | GO:0008144; drug binding | 3.378E-05 | 5.254E-02 | AURKA, AURKB, CYP1A1, CYP1B1, KDR, PIM1 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 3.700E-05 | 5.371E-02 | CYP1A1, CYP1B1, KDR, NPC1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.034E-05 | 5.490E-02 | CYP1A1, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 4.858E-05 | 5.877E-02 | CYP1A1, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.858E-05 | 5.877E-02 | CYP1A1, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:1903409; reactive oxygen species biosynthetic process | 5.298E-05 | 6.072E-02 | CYP1A1, CYP1B1 |
| CC | GO:0043226; organelle | GO:0051233; spindle midzone | 8.911E-05 | 8.436E-02 | AURKA, AURKB |
| MF | GO:0005488; binding | GO:0000166; nucleotide binding | 1.035E-04 | 9.038E-02 | AURKA, AURKB, GFER, KDR, PIM1, RAB9A |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 2.627E-04 | 1.631E-01 | AURKA, AURKB |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 2.870E-04 | 1.631E-01 | AURKA, AURKB, CYP1A1, CYP1B1, GFER, KDR, NPC1, PIM1, RAB9A |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.392E-04 | 2.154E-03 | CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.181E-04 | 2.154E-03 | CYP1A1, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.937E-04 | 2.154E-03 | CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.653E-04 | 2.559E-03 | CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.867E-04 | 2.582E-03 | CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 7.385E-03 | 2.708E-02 | PIM1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.536E-02 | 7.059E-02 | PIM1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.712E-02 | 7.059E-02 | KDR |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 4.455E-02 | 9.801E-02 | PIM1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.888E-02 | 7.059E-02 | CYP1A1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | AURKA; KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AURKA; AURKB; KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA; |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | KDR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | KDR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKA; AURKB; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | AML | NA | KDR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
